Discovery of a Thiadiazole–Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models-Reference-Cited by-同舟云学术

Discovery of a Thiadiazole–Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models

Published:2019-06-14 Issue:14 Volume:62 Page:6540-6560
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Finlay M. Raymond V.¹^ORCID,Anderton Mark¹,Bailey Andrew¹,Boyd Scott¹,Brookfield Joanna²,Cairnduff Ceri²,Charles Mark²,Cheasty Anne²,Critchlow Susan E.¹,Culshaw Janet¹,Ekwuru Tennyson²,Hollingsworth Ian¹,Jones Neil²,Leroux Fred²,Littleson Mairi¹^ORCID,McCarron Hollie²,McKelvie Jennifer²,Mooney Lorraine¹,Nissink J. Willem M.¹^ORCID,Perkins David¹,Powell Steve¹,Quesada Mar Jimenez²,Raubo Piotr¹,Sabin Verity²,Smith James²,Smith Peter D.¹^ORCID,Stark Andrew¹,Ting Attilla¹,Wang Peng³,Wilson Zena¹,Winter-Holt Jon J.¹,Wood J. Matthew¹,Wrigley Gail L.¹,Yu Guoqing³,Zhang Peng³

Affiliation:

1. Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom

2. Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom

3. Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00260

Reference31 articles.

1. Targeting Metabolism for Cancer Therapy